{"id":"W2403244649","doi":"10.1007/s12072-016-9737-2","title":"Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure","year":2016,"lang":"en","type":"article","venue":"Hepatology International","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network","funders":"Bristol-Myers Squibb","keywords":"Entecavir; Medicine; Adefovir; Telbivudine; Lamivudine; Internal medicine; Regimen; Gastroenterology; Clinical endpoint; Hepatitis B virus; Emtricitabine; Chronic hepatitis; Hepatitis B; Tenofovir; Virology; Virus; Human immunodeficiency virus (HIV); Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":{"n_in":0,"stratum":"aff_core","weight":5595.2375,"opus":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Clinical study of entecavir plus tenofovir in chronic hepatitis B after treatment failure; a therapeutic efficacy question."},"gpt":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"This clinical study concerns combination therapy for chronic hepatitis B, not research practice."},"grok":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"low","reason":"Clinical hepatology combination therapy for chronic hepatitis B; domain medicine, abstract missing."}},"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006130923,0.0003403672,0.0009596733,0.0003800698,0.0005760157,0.0005482989,0.0001966494,0.000520127,0.001581353],"category_scores_gemma":[0.00129287,0.00019649,0.0006967075,0.000502518,0.0002556252,0.0005762947,0.0002227413,0.0005998714,0.0001943584],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003995399,"about_ca_system_score_gemma":0.0006036737,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001429781,"about_ca_topic_score_gemma":0.004348305,"domain_scores_codex":[0.9997134,0.0001304775,0.00003906892,0.00002305145,0.00003569036,0.00005835425],"domain_scores_gemma":[0.9995927,0.0001255637,0.0000679324,0.00001470672,0.00001892714,0.0001801189],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1100904,0.00391092,0.6639282,0.001223664,0.002257896,0.006523688,0.0007400168,0.0007138998,0.007259799,0.0002598398,0.003755966,0.1993357],"study_design_scores_gemma":[0.01769309,0.05454609,0.9032581,0.0005284919,0.001973658,0.007858366,0.001099036,0.001141481,0.001644446,0.0002746349,0.009911894,0.00007072269],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871875,0.009666394,0.00005365637,0.000419253,0.00008899954,0.00005409422,0.0001086689,0.000008011816,0.002413582],"genre_scores_gemma":[0.9968778,0.002294779,0.00009822614,0.0002194241,0.00006599694,0.00002565541,0.0001142237,0.000001467739,0.0003023876],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001581353,"threshold_uncertainty_score":0,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01256145636385307,"score_gpt":0.2666954359512057,"score_spread":0.2541339795873526,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}